Semaglutide vs. Tirzepatide: Comparing GLP-1 Medications for Palm Beach County Patients
Semaglutide vs. Tirzepatide: Comparing GLP-1 Medications
Semaglutide and tirzepatide have reshaped how weight management and type 2 diabetes are treated. Both are FDA-approved, but they work differently and fit different patients. MedClub by Dr. Jenn provides medically supervised GLP-1 consultations for patients throughout Palm Beach County, Florida, including West Palm Beach, Boca Raton, and surrounding communities. Here’s how the two medications compare.
What Is Semaglutide?
Semaglutide (Ozempic®/Wegovy®) has been FDA-approved for type 2 diabetes since 2017, and for chronic weight management since 2021. It works by mimicking GLP-1, a hormone that helps regulate appetite and blood sugar.
What Is Tirzepatide?
Tirzepatide (Mounjaro®/Zepbound®) is FDA-approved for type 2 diabetes and chronic weight management. It works by mimicking two hormones — GLP-1 and GIP — which together help regulate blood sugar and appetite.
Semaglutide: Considerations
Potential benefits: significant weight loss, effective blood sugar management, a well-established long-term safety record, once-weekly dosing, and an FDA-recognized reduction in cardiovascular event risk for eligible patients.
Potential drawbacks: gastrointestinal side effects (nausea, vomiting, diarrhea) are common; cost can be a barrier depending on coverage; it isn’t appropriate for everyone, including certain medical histories or during pregnancy; and ongoing monitoring is needed.
Trial Snapshot — STEP 1
Wilding JPH, et al. New England Journal of Medicine, 2021.
1,961 adults with overweight/obesity, 68 weeks: 14.9% mean weight reduction with semaglutide vs. 2.4% with placebo.
View full trial publication →
Tirzepatide: Considerations
Potential benefits: a dual-hormone mechanism that some patients find leads to more pronounced weight loss and blood sugar control, appetite reduction, and once-weekly dosing.
Potential drawbacks: as a newer medication, its long-term data is still growing compared to semaglutide; gastrointestinal side effects are common; and cost or access can vary.
Trial Snapshot — SURMOUNT-1
Jastreboff AM, et al. New England Journal of Medicine, 2022.
2,539 adults with obesity/overweight, 72 weeks: up to 20.9% mean weight reduction at the 15mg dose vs. 3.1% with placebo.
View full trial publication →
Emerging Research: Retatrutide
Retatrutide is an investigational medication — it is not FDA-approved and is not currently available by prescription. It is a triple-hormone agonist (targeting GLP-1, GIP, and glucagon receptors). Retatrutide is not offered through MedClub, and this information is provided for educational awareness only, not as a treatment recommendation. We’ll share updates if and when it receives FDA approval.
Trial Snapshot — Phase 2 Obesity Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. New England Journal of Medicine, 2023.
48 weeks: up to 24.2% mean weight reduction at the highest dose studied vs. placebo. Retatrutide has since advanced into Phase 3 trials, which are still ongoing and not yet the basis for FDA approval.
View full trial publication →
Final Thoughts
Semaglutide and tirzepatide are both effective, FDA-approved options for weight management and type 2 diabetes, but they work through different mechanisms and may suit different patients. Semaglutide enhances insulin secretion, reduces appetite, and slows gastric emptying through the GLP-1 pathway alone. Tirzepatide adds a second hormone pathway (GIP) to that approach, which some patients find leads to more pronounced results. The right choice depends on your individual health history, goals, and how your body responds — which is exactly what a consultation is for.
Eligibility
To qualify for a GLP-1 weight management program in most states, a Body Mass Index (BMI) of 27 or above and a recent physical exam are typically required. Certain health histories — including pancreatic cancer or chronic constipation — may affect whether a GLP-1 medication is appropriate for you.
Quick BMI Calculator
This calculator is for general reference only and does not determine program eligibility on its own. Your provider will confirm your BMI and eligibility during your evaluation. Prefer an official source? Use the CDC’s calculator.
Frequently Asked Questions
Do I need to visit the clinic in person for a GLP-1 consultation?
Semaglutide and tirzepatide consultations at MedClub by Dr. Jenn are available for patients throughout Palm Beach County, Florida, with both telehealth and in-person options depending on your treatment plan.
What BMI do I need to qualify for a GLP-1 program in Florida?
Most GLP-1 weight management programs require a BMI of 27 or above, along with a recent physical exam and provider evaluation. Your exact eligibility is confirmed by your provider, not by a self-reported calculator.
Is retatrutide available at MedClub?
No. Retatrutide is investigational and not FDA-approved. MedClub does not offer retatrutide; this article discusses it for educational awareness only.
Interested in a consultation with our providers?
Call our Palm Beach clinic: 561-214-3323
FDA Disclaimer
This article is provided for general educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. It is not a substitute for a one-on-one evaluation with a licensed healthcare provider. Statements regarding retatrutide describe an investigational medication that has not been evaluated or approved by the FDA for safety, efficacy, or quality, and it is not offered by MedClub.
Semaglutide and tirzepatide are FDA-approved medications, but their appropriateness for any individual patient — including eligibility, dosing, and expected results — is determined by a licensed provider based on personal health history. Individual results vary, and outcomes are not guaranteed.